Opioid prescribing in general practice: use of a two-stage review tool to identify and assess high-dose prescribing

Abstract

Background:

Long-term opioid analgesic prescribing in chronic non-cancer pain (CNCP) is a growing worldwide concern. This has implications for optimal healthcare management in general and chronic pain management specifically. This work documents the development of a review tool and its use in the South West of England in a locality that showed opioid prescribing levels higher than surrounding localities.

Methods:

An electronic tool which enabled calculation of total prescribed morphine-equivalent doses was developed to allow general practitioners (GPs) to undertake reviews of CNCP patients. This tool was used to assess strong opioid prescribing over a 3-month period at every GP practice (n = 41) in the locality. Every prescription for morphine, oxycodone, pethidine and fentanyl during this period was included.

Aspects assessed included drug(s) prescribed, dose prescribed, whether tramadol was prescribed concurrently, whether the drugs were potentially being overused and/or whether the patient was in palliative care. Patients prescribed over 120 mg morphine equivalent per day were reviewed in greater depth, as this is an indication for specialist input.

Results:

In total, 1881 patients received a prescription in the assessment period. Morphine was the most commonly prescribed drug (n = 847). In all, 363 CNCP patients were prescribed a dose equal to or above 120 mg morphine a day, with a maximum morphine-equivalent dose of 890 mg being prescribed. Over 11% (n = 211) of patients were concurrently prescribed tramadol. The most frequently cited reason for prescription of high-dose opioids was found to be a musculoskeletal pain of the back, neck, joints or limbs. The care of 85 specific CNCP patients was reviewed and optimised.

Discussion:

No published work to date has documented such an in-depth analysis of primary-care opioid analgesic prescribing utilising prescriber data. Assessing total-dose morphine-equivalent prescribing using this method provides valuable insights into the potential need for urgent medication review. The tool developed may be of value to other GP practices following validation.

Keywords

Analgesia chronic pain opioid analgesics pain pain management primary health care

Get full access to this article

View all access options for this article.

References

Ruscitto

Smith

Guthrie

Changes in opioid and other analgesic use 1995-2010: repeated cross-sectional analysis of dispensed prescribing for a large geographical population in Scotland. Eur J Pain 2015; 19(1): 59–66.

Zin

Chen

Knaggs

RD.

Changes in trends and pattern of strong opioid prescribing in primary care. Eur J Pain 2014; 18(9): 1343–1351.

Chou

Fanciullo

Fine

et al . Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10(2): 113–130.

Boudreau

Von Korff

Rutter

et al . Trends in long-term opioid therapy for chronic non-cancer pain. Pharmacoepidemiol Drug Saf 2009; 18(12): 1166–1175.

Von Korff

. Opioids for chronic musculoskeletal pain: putting patient safety first. Pain 2013; 154(12): 2583–2585.

Manchikanti

Helm

2nd Fellows

et al . Opioid epidemic in the United States. Pain Physician 2012; 15(3 Suppl.): ES9–ES38.

Nelson

Perrone

Curbing the opioid epidemic in the United States: the risk evaluation and mitigation strategy (REMS). JAMA 2012; 308(5): 457–458.

Okie

A flood of opioids, a rising tide of deaths. N Engl J Med 2010; 363(21): 1981–1985.

Stannard

Opioid prescribing in the UK: can we avert a public health disaster?

Br J Pain 2012; 6(1): 7–8.

10.

The British Pain Society. Opioids for persistent pain: good practice. London: The British Pain Society, 2010.

11.

The Royal College of Anaesthetists. Opioids aware: a resource for patients and healthcare professionals to support prescribing of opioid medicines for pain. London: The Royal College of Anaesthetists, http://www.rcoa.ac.uk/faculty-of-pain-medicine/opioids-aware (2015, accessed 9 November 2017).

12.

Chou

Turner

Devine

et al . The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop. Ann Intern Med 2015; 162(4): 276–286.

13.

Noble

Treadwell

Tregear

et al . Long-term opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010; 1: CD006605.

14.

Chaparro

Furlan

Deshpande

et al . Opioids compared with placebo or other treatments for chronic low back pain: an update of the Cochrane Review. Spine (Phila Pa 1976) 2014; 39(7): 556–563.

15.

Chaparro

Furlan

Deshpande

et al . Opioids compared to placebo or other treatments for chronic low-back pain. Cochrane Database Syst Rev 2013; 8: CD004959.

16.

Painter

Crofford

LJ.

Chronic opioid use in fibromyalgia syndrome: a clinical review. J Clin Rheumatol 2013; 19(2): 72–77.

17.

Fitzcharles

Ste-Marie

Gamsa

et al . Opioid use, misuse, and abuse in patients labeled as fibromyalgia. Am J Med 2011; 124(10): 955–960.

18.

Huber

Robinson

Noe

et al . Who benefits from chronic opioid therapy? Rethinking the question of opioid misuse risk. Healthcare (Basel) 2016; 4(2): 29.

19.

Deyo

Von Korff

Duhrkoop

Opioids for low back pain. BMJ 2015; 350: g6380.

20.

Goldenberg

Clauw

Palmer

et al . Opioid use in fibromyalgia: a cautionary tale. Mayo Clin Proc 2016; 91(5): 640–648.

21.

Von Korff

Kolodny

Deyo

et al . Long-term opioid therapy reconsidered. Ann Intern Med 2011; 155(5): 325–328.

22.

Gureje

Simon

Von Korff

A cross-national study of the course of persistent pain in primary care. Pain 2001; 92(1–2): 195–200.

23.

McCracken

Velleman

Eccleston

Patterns of prescription and concern about opioid analgesics for chronic non-malignant pain in general practice. Prim Health Care Res 2008; 9(02): 146–156.

24.

Blake

Leighton

van der Walt

et al . Prescribing opioid analgesics for chronic non-malignant pain in general practice – a survey of attitudes and practice. Br J Pain 2015; 9(4): 225–232.

25.

Song

Foell

An exploration of opioid medication management for non-malignant pain in primary care. Br J Pain 2015; 9(3): 181–189.

26.

Public Health England (PHE). Plymouth Unitary Authority health profile 2014, http://www.apho.org.uk/resource/item.aspx?RID=142335 (2014, accessed 9 November 2017).

27.

Home Office, UK, Controlled drugs regulations (Misuse of Drugs Regulations). Report, December 2001.

28.

Edlund

Martin

Fan

et al . Risks for opioid abuse and dependence among recipients of chronic opioid therapy: results from the TROUP study. Drug Alcohol Depend 2010; 112(1–2): 90–98.

29.

Washington State Agency Medical Directors’ Group (AMDG). Interagency guideline on opioid dosing for chronic non-cancer pain: an educational aid to improve care and safety with opioid therapy. Washington, DC: AMDG, 2010, http://www.agencymeddirectors.wa.gov/files/opioidgdline.pdf (accessed 9 November 2017).

30.

Grünenthal Ltd. Summary of product characteristics – Zydol capsules. Uxbridge: Grünenthal Ltd., 2015.

31.

UK Medicines Information (UKMi). What are the equivalent doses of oral morphine to other oral opioids when used as analgesics in adult palliative care? Southampton: Wessex Drug and Medicines Information Centre, University Hospital Southampton NHS Foundation Trust, 2011.

32.

Home Office, UK, The Misuse of Drugs Misuse of Drugs (Safe Custody) (Amendment) (England, Wales Scotland) Regulations, 2014.

33.

Selby and York Palliative Care Team and Pharmacy Group. York Hospitals NHS Foundation Trust and NHS North Yorkshire and York. Palliative care analgesic dose conversion, 2009.

34.

McAuley

GlobalRPh – opioid analgesic converter, http://globalrph.com/narcoticonv.htm (2012, accessed 9 December 2016).

35.

NHS South Region. Controlled drug newsletter, https://www.england.nhs.uk/south/wp-content/uploads/sites/6/2016/07/nhs-cd-newsletter-july16.pdf (2016, accessed 31 August 2016).

36.

Whitehouse

Marr

Oral morphine is a prescription-only medicine. Anaesthesia 2014; 69(10): 1179.

37.

Samaha

Robinson

TE.

Why does the rapid delivery of drugs to the brain promote addiction?

Trends Pharmacol Sci 2005; 26(2): 82–87.

38.

Task Force on Medicines Partnership and The National Collaborative Medicines Management Services Programme. Room for review. A guide to medication review: the agenda for patients, practitioners and managers. London: Medicines Partnership, 2002.

39.

Clyne

WBA

Seal

. A guide to medication review. Keele University: NPC Plus & Medicines Partnership, 2008.

40.

Seamark

Greaves

et al . GPs prescribing of strong opioid drugs for patients with chronic non-cancer pain: a qualitative study. Br J Gen Pract 2013; 63(617): e821–188.

41.

Home Office. Learning from tragedy, keeping patients safe. Overview of the Government’s action programme in response to the recommendations of the Shipman Inquiry. London: The Stationery Office, 2007, https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/228886/7014.pdf (accessed 9 November 2017).

42.

Latta

Ginsberg

Barkin

RL.

Meperidine: a critical review. Am J Ther 2002; 9(1): 53–68.

43.

Dunn

Hay

EM.

Opioids for chronic musculoskeletal pain. BMJ 2010; 341: c3533.

44.

Ballantyne

Shin

NS.

Efficacy of opioids for chronic pain: a review of the evidence. Clin J Pain 2008; 24(6): 469–478.

45.

Department of Health. Drug misuse and dependence: UK guidelines on clinical management. London: Department of Health, 2007.

46.

Home Office, UK, The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014, Sess. (2014).